Clarus Therapeutics and HavaH Therapeutics Announce Licensing Agreement for Product to Treat Androgen-Dependent Inflammatory Breast Disease and Certain Forms of Breast Cancer

Clarus Therapeutics, Inc. and HavaH Therapeutics announced a licensing agreement whereby Clarus will acquire the development and commercialization rights for CLAR-121. If approved, CLAR-121 would be the first T treatment of its kind for inflammatory breast disease, including estrogen receptor-positive breast cancer.